The Korean Journal of Physiology and Pharmacology

  • 제25권5호
  • /
  • Pages.459-466
  • /
  • 2021
  • /
  • 1226-4512(pISSN)
  • /
  • 2093-3827(eISSN)
대한약리학회 (The Korean Society of Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Dronedarone hydrochloride enhances the bioactivity of endothelial progenitor cells via regulation of the AKT signaling pathway

  • Zhang, Jian (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Le, Thi Hong Van (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Rethineswaran, Vinoth Kumar (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Kim, Yeon-Ju (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Jang, Woong Bi (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Ji, Seung Taek (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Ly, Thanh Truong Giang (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Ha, Jong Seong (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Yun, Jisoo (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital) ;
  • Cheong, Jae Hun (Department of Molecular Biology, Pusan National University) ;
  • Jung, Jinsup (Department of Physiology, School of Medicine, Pusan National University) ;
  • Kwon, Sang-Mo (Laboratory for Vascular Medicine and Stem Cell Biology, Research Institute of Convergence Biomedical Science and Technology, Pusan National University Yangsan Hospital)
  • 투고 : 2021.03.23
  • 심사 : 2021.07.07
  • 발행 : 2021.09.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Cardiovascular disease (CVD) and its complications are the leading cause of morbidity and mortality in the world. Because of the side effects and incomplete recovery from current therapy, stem cell therapy emerges as a potential therapy for CVD treatment, and endothelial progenitor cell (EPC) is one of the key stem cells used for therapeutic applications. The effect of this therapy required the expansion of EPC function. To enhance the EPC activation, proliferation, and angiogenesis using dronedarone hydrochloride (DH) is the purpose of this study. DH received approval for atrial fibrillation treatment and its cardiovascular protective effects were already reported. In this study, DH significantly increased EPC proliferation, tube formation, migration, and maintained EPCs surface marker expression. In addition, DH treatment up-regulated the phosphorylation of AKT and reduced the reactive oxygen species production. In summary, the cell priming by DH considerably improved the functional activity of EPCs, and the use of which might be a novel strategy for CVD treatment.

키워드

과제정보

This work was supported by a grant from the National Research Foundation (NRF-2015R1A5A2009656 and 2018R1A2B6007478), Korean Health Technology R&D Project, Ministry of Health and Welfare (HI18C2459); the Technology innovation Program (No. 20000325, Development of tissue engineered blood vessels using tissue specific bioink and 3D printing technique) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea); and was funded by the Korean government.

참고문헌

  1. Cully M. Cardiovascular disease: BET inhibitor attenuates heart failure. Nat Rev Drug Discov. 2017;16:453. https://doi.org/10.1038/nrd.2017.125
  2. Dimmeler S. Cardiovascular disease review series. EMBO Mol Med. 2011;3:697. https://doi.org/10.1002/emmm.201100182
  3. Kuehn BM. Sleep duration linked to cardiovascular disease. Circulation. 2019;139:2483-2484. https://doi.org/10.1161/CIRCULATIONAHA.119.041278
  4. Yoshida Y, Yamanaka S. Recent stem cell advances: induced pluripotent stem cells for disease modeling and stem cell-based regeneration. Circulation. 2010;122:80-87. https://doi.org/10.1161/CIRCULATIONAHA.109.881433
  5. Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275:964-967. https://doi.org/10.1126/science.275.5302.964
  6. Sen S, McDonald SP, Coates PT, Bonder CS. Endothelial progenitor cells: novel biomarker and promising cell therapy for cardiovascular disease. Clin Sci (Lond). 2011;120:263-283. https://doi.org/10.1042/CS20100429
  7. Zhao T, Li J, Chen AF. MicroRNA-34a induces endothelial progenitor cell senescence and impedes its angiogenesis via suppressing silent information regulator 1. Am J Physiol Endocrinol Metab. 2010;299:E110-E116.
  8. Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:208-216. https://doi.org/10.1161/ATVBAHA.107.155317
  9. Shintani S, Murohara T, Ikeda H, Ueno T, Honma T, Katoh A, Sasaki K, Shimada T, Oike Y, Imaizumi T. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation. 2001;103:2776-2779. https://doi.org/10.1161/hc2301.092122
  10. Lee JH, Lee SH, Choi SH, Asahara T, Kwon SM. The sulfated polysaccharide fucoidan rescues senescence of endothelial colonyforming cells for ischemic repair. Stem Cells. 2015;33:1939-1951. https://doi.org/10.1002/stem.1973
  11. Naccarelli GV, Wolbrette DL, Levin V, Samii S, Banchs JE, Penny-Peterson E, Gonzalez MD. Safety and efficacy of dronedarone in the treatment of atrial fibrillation/flutter. Clin Med Insights Cardiol. 2011;5:103-119. https://doi.org/10.4137/CMC.S6677
  12. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100:2276-2281. https://doi.org/10.1161/01.CIR.100.22.2276
  13. Sun W, Sarma JS, Singh BN. Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. J Cardiovasc Pharmacol. 2002;39:677-684. https://doi.org/10.1097/00005344-200205000-00008
  14. Pisters R, Hohnloser SH, Connolly SJ, Torp-Pedersen C, Naditch-Brule L, Page RL, Crijns HJ. Effect of dronedarone on clinical end points in patients with atrial fibrillation and coronary heart disease: insights from the ATHENA trial. Europace. 2014;16:174-181. https://doi.org/10.1093/europace/eut293
  15. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp-Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678. https://doi.org/10.1056/NEJMoa0803778
  16. Hur J, Yoon CH, Lee CS, Kim TY, Oh IY, Park KW, Kim JH, Lee HS, Kang HJ, Chae IH, Oh BH, Park YB, Kim HS. Akt is a key modulator of endothelial progenitor cell trafficking in ischemic muscle. Stem Cells. 2007;25:1769-1778. https://doi.org/10.1634/stemcells.2006-0385
  17. Kim YJ, Ji ST, Kim DY, Jung SY, Kang S, Park JH, Jang WB, Yun J, Ha J, Lee DH, Kwon SM. Long-term priming by three small molecules is a promising strategy for enhancing late endothelial progenitor cell bioactivities. Mol Cells. 2018;41:582-590. https://doi.org/10.14348/MOLCELLS.2018.0011
  18. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149:274-293. https://doi.org/10.1016/j.cell.2012.03.017
  19. Rethineswaran VK, Kim YJ, Jang WB, Ji ST, Kang S, Kim DY, Park JH, Van LTH, Giang LTT, Ha JS, Yun J, Lee DH, Yu SN, Park SG, Ahn SC, Kwon SM. Enzyme-aided extraction of fucoidan by AMG augments the functionality of EPCs through regulation of the AKT/Rheb signaling pathway. Mar Drugs. 2019;17:392. https://doi.org/10.3390/md17070392
  20. Adler V, Yin Z, Tew KD, Ronai Z. Role of redox potential and reactive oxygen species in stress signaling. Oncogene. 1999;18:6104-6111. https://doi.org/10.1038/sj.onc.1203128
  21. Lander HM, Milbank AJ, Tauras JM, Hajjar DP, Hempstead BL, Schwartz GD, Kraemer RT, Mirza UA, Chait BT, Burk SC, Quilliam LA. Redox regulation of cell signalling. Nature. 1996;381:380-381. https://doi.org/10.1038/381380a0
  22. Fleissner F, Thum T. Critical role of the nitric oxide/reactive oxygen species balance in endothelial progenitor dysfunction. Antioxid Redox Signal. 2011;15:933-948. https://doi.org/10.1089/ars.2010.3502
  23. Kawamoto A, Asahara T, Losordo DW. Transplantation of endothelial progenitor cells for therapeutic neovascularization. Cardiovasc Radiat Med. 2002;3:221-225. https://doi.org/10.1016/S1522-1865(03)00082-9
  24. Alev C, Ii M, Asahara T. Endothelial progenitor cells: a novel tool for the therapy of ischemic diseases. Antioxid Redox Signal. 2011;15:949-965. https://doi.org/10.1089/ars.2010.3872
  25. Kawamoto A, Asahara T. Role of progenitor endothelial cells in cardiovascular disease and upcoming therapies. Catheter Cardiovasc Interv. 2007;70:477-484. https://doi.org/10.1002/ccd.21292
  26. Lamichane S, Baek SH, Kim YJ, Park JH, Dahal Lamichane B, Jang WB, Ji S, Lee NK, Dehua L, Kim DY, Kang S, Seong HJ, Yun J, Lee DH, Moon HR, Chung HY, Kwon SM. MHY2233 attenuates replicative cellular senescence in human endothelial progenitor cells via SIRT1 signaling. Oxid Med Cell Longev. 2019;2019:6492029.
  27. Incalza MA, D'Oria R, Natalicchio A, Perrini S, Laviola L, Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1-19. https://doi.org/10.1016/j.vph.2017.05.005